Business
Indiana University Medical School collaboration
Indiana University Medical School collaboration.
About this update from Genincode Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6560F\n GENinCode PLC\n 23 March 2022\n \n \n \n \n \n \n \n GENinCode Plc\n \n \n (\"GENinCode\" or the \"Company\")\n \n \n \n \n \n \n Collaboration\n \n \n with Indiana University School of Medicine \n \n \n \n \n Study for testing \n \n \n Cardio inCode-SCORE for the risk of onset of cardiovascular disease\n \n \n \n \n \n \n Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the Indiana University School of Medicine (\"IU\"). IU is the largest medical school in the US and will undertake a 'Proof of Concept' study using Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease (\"ASCVD\n \"). ASCVD accounts for over 85% of all cardiovascular disease deaths and is\n the leading cause of morbidity and mortality in the US and globally. \n \n \n \n \n \n According to the Centres for Disease Control and Prevention (\"CDC\"), cardiovascular disease (\"CVD\") is the number one cause of death in the United States and the decades‐long trend towards lower cardiovascular mortality rates has begun to reverse, with an increase in total mortality during recent years: \n \n https://www.cdc.gov/heartdisease/facts.htm\n \n .\n \n \n \n \n \n CVD disproportionately affects people of lower socioeconomic status, and those of non‐white ethnicity. Early identification of subclinical disease in the population can lead to better primary prevention of heart attack and stroke. Current American College of Cardiology (\"ACC\") \n guidelines\n call for risk stratification using validated instruments, such as the US National Heart Lung and Blood Institute (\"NHLBI\") pooled risk cohort equation, drawing on clinical parameters readily available such as blood pressure and cholesterol levels. In addition, the \n guidelines\n endorse the use of \"risk enhancing factors\" such as the Coronary Artery Calcium (\"CAC\") score, undertaken using \n computerised\n tomography (\"CT\") imaging of the coronary arteries. \n \n \n \n \n \n Whilst acknowledging family history as a risk factor, current guidelines have not yet incorporated the potential of genetic risk assessment in the prediction of ASCVD. Cardio inCode-SCORE provides an opportunity to...